Skip to main content

Table 1 (abstract O3). Subject characteristics

From: Proceedings of the 2018 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Scientific Meeting

  All, # (%)
50 subjects
CTP A, # (%)
15 subjects
CTP B, # (%)
24 subjects
CTP C, # (%)
11 subjects
P value
Female 35 (70.0) 11 (73.3) 16 (66.7) 8 (72.7) NS
Caucasian 46 (92.0) 13 (86.7) 23 (95.8) 10 (90.9) NS
Age of onset
 Median (IQR)
9.62 (6.3, 11.6) 9.30 (6.9, 11.9) 9.27 (4.8, 10.5) 10.3 (5.7, 13.4) NS
Age at study entry
 Median (IQR)
13 (9.8, 14.5) 13.2 (9.8, 14.1) 11.9 (6.8, 15.2) 13.3 (11.2, 14.3) NS
Subtype:      0.011
 Circumscribed superficial 4 (8.0) 0 1 (4.2) 3 (27.3)
 Circumscribed deep 3 ( 6.0) 0 0 3 (27.3)
 Linear head 12 (24.0) 3 (20.0) 6 (25.0) 3 (27.3)
 Linear trunk/limb 18 (36.0) 8 (53.3) 9 (37.5) 1 (9.1)
 Generalized 5 (10.0) 2 (13.3) 3 (12.5) 0
 Pansclerotic 1 (2.0) 0 1 (4.2) 0
 Mixed 6 (12.0) 2 (13.3) 4 (16.7) 0
Anatomic Location      
 Head 20 (40.0) 4 (26.7) 11 (45.8) 5 (45.5) NS
 Trunk 23 (46.0) 7 (46.7) 11 (45.8) 5 (45.5) NS
 Limb 29 (58.0) 11 (73.3) 15 (62.5) 3 (27.3) 0.052
Prior Systemic
Treatment
9 (18.0) 2 (13.3) 7 (29.2) 0 0.097
ANA positivity 23 (54.8) 5 (41.7) 15 (79.0) 3 (27.3) 0.013
Extracutaneous morbidity 37 (74.0) 11 (73.3) 18 (75.0) 8 (72.7) NS
Deviation from CTP 24 (48.0) 8 (53.3) 11 (45.8) 5 (45.5) NS
MD Activity status at 12 months vs baseline      NS
 Major improvement 22 (50.0) 4 (33.3) 13 (56.5) 5 (55.5)
 Moderate improvement 15 (34.1) 6 (50.0) 7 (30.4) 2 (22.2)
 Mild improvement 6 (13.6) 2 (16.7) 2 (8.7) 2 (22.2)
 Mild worsening 1 (2.3) 0 1 (4.4) 0
Inadequate response to CTP 13 (26.0) 4 (33.3) 8 (33.3) 1 (9.1) NS
Any Adverse Event 33 (66.0) 7 (46.7) 17 (70.8) 9 (81.8) NS
AE grade 1 26 (52.0) 6 (40.0) 11 (45.8) 9 (81.8) NS
AE grade 2 22 (44.0) 4 (26.7) 14 (58.3) 4 (36.4) NS
AE Grade 3 1 (2.3) 0 1 (4.4) 0 NS